Baoji Xianghui Dingsheng Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Baoji Xianghui Dingsheng Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include FEHEOO. The owner is based in Baoji Shaanxi.

No. 022, Group 3, Quliubao Village

Tangyu Town, Mei County

Baoji Shaanxi 722300 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FEHEOO
FEHEOO
Registered 2024

Trademark Classifications

Baoji Xianghui Dingsheng Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Baoji Xianghui Dingsheng Technology Co., Ltd. have?

Baoji Xianghui Dingsheng Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Baoji Xianghui Dingsheng Technology Co., Ltd. file in?

Baoji Xianghui Dingsheng Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Baoji Xianghui Dingsheng Technology Co., Ltd.'s most well-known trademarks?

Baoji Xianghui Dingsheng Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as FEHEOO. These are among 1 currently registered trademark in the portfolio.

What is Baoji Xianghui Dingsheng Technology Co., Ltd.'s trademark registration success rate?

Baoji Xianghui Dingsheng Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.